Physician profile
Asem Werdi
NPI 1588953038
$2,120.40
in general payments reported to CMS, 2019-2025
37 companies · $28.35 in 2025
The $28.35 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $189 · 2021: $334 · 2022: $221 · 2023: $250 · 2024: $469 · 2025: $28.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $395.09 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $256.23 | 2019-2025 | |
| Mannkind Corporation | $133.27 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $110.41 | 2019-2024 | |
| Lilly USA, LLC | $108.27 | 2021-2024 | Mounjaro, Zepbound |
| Abbvie INC. | $89.15 | 2019-2024 | |
| Allergan, INC. | $88.62 | 2019-2020 | |
| Amarin Pharma, INC. | $85.01 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.81 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $70.65 | 2019-2024 | Lokelma, Airsupra |
| Novo Nordisk INC | $69.51 | 2019-2023 | Ozempic, Rybelsus |
| Shire North American Group INC | $50.33 | 2019 | |
| Pfizer INC. | $47.42 | 2020-2021 | |
| Lundbeck LLC | $41.55 | 2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $38.65 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $36.76 | 2021-2023 | Tirosint, Licart |
| Xeris Pharmaceuticals, INC. | $35.73 | 2021-2022 | |
| Corcept Therapeutics | $31.43 | 2019-2020 | |
| Dexcom, INC. | $29.54 | 2022 | |
| Ardelyx, INC. | $27.00 | 2024 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $26.39 | 2023 | Rexulti |
| Madrigal Pharmaceuticals | $25.46 | 2024 | Resmetirom |
| Ultragenyx Pharmaceutical INC. | $23.33 | 2024 | Crysvita |
| Melinta Therapeutics, LLC | $20.35 | 2019 | |
| Hologic Sales and Service, LLC | $20.04 | 2022 | |
| Roche Diabetes Care, INC. | $19.28 | 2021 | |
| Edwards Lifesciences Corporation | $18.67 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Paratek Pharmaceuticals, INC. | $17.73 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.93 | 2020 | |
| Exact Sciences Corporation | $16.57 | 2023 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $16.53 | 2020 | |
| Halozyme INC | $16.29 | 2023 | |
| Amgen INC. | $14.14 | 2024 | Otezla, Repatha |
| Philips North America LLC | $13.95 | 2024 | (Ck7) Extended Holter |
| Intuity Medical INC | $13.94 | 2022 | |
| Abbott Laboratories | $12.38 | 2019 | |
| Theracosbio, LLC | $10.99 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asem Werdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.